On March 26, a groundbreaking study led by Academician Xuehao Wang from the Hepatobiliary Center of the First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital) was published in Journal of Hepatology, a top-tier international journal in gastroenterology and hepatology and the official journal of the European Association for the Study of the Liver (EASL). The paper, titled eIF3f promotes tumour malignancy by remodelling fatty acid biosynthesis in hepatocellular carcinoma, is published in a Tier 1 journal recognized by the Chinese Academy of Sciences, with an impressive Impact Factor of 26.8 (2023) and a projected Impact Factor of 32.4 (2024). Academician Xuehao Wang served as the corresponding author, with Qing Li as co-corresponding author and Suiqing Zhou as the first author.
This study, employing multi-omics approaches and diverse models, is the first to uncover that eIF3f is significantly overexpressed in hepatocellular carcinoma (HCC) and is correlated with poor prognosis. Mechanistic investigations demonstrated that eIF3f remodels fatty acid metabolism in HCC, fostering an immunosuppressive tumor microenvironment and driving malignant progression. Notably, targeting eIF3f was shown to enhance the efficacy of immunotherapy in HCC, suggesting its potential as both a prognostic biomarker and therapeutic target for HCC patients.
Academician Xuehao Wang's team has dedicated years to systematic and in-depth research on HCC. Their groundbreaking studies have garnered widespread recognition in the international scientific community, significantly advancing the understanding of HCC pathogenesis while providing novel theoretical foundations and innovative approaches for clinical diagnosis and treatment. Recently, the team has published numerous high-impact studies in prestigious journals including Cell Metabolism, Journal of Hepatology, Nature Communications, Hepatology, Science Translational Medicine, Signal Transduction and Targeted Therapy, and Advanced Materials. These publications have established crucial theoretical frameworks and clinical strategies for HCC management.
(Drafted by the Pancreas Center of the First Affiliated Hospital, NMU; Reviewed by Jiang Kuirong; Translated by Zhang Bei)
